Corrigendum

Abstract

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des Devel Ther. 2011;5:211–224. The following sections are direct quotes from Cerny and Cerny ( Hum Vaccin. 2009;5(4):200–205). The second, third, and fourth sentences of the abstract, as well as the last paragraph of the abstract, except for the second sentence (pp. 211) ‘Vaccines against nicotine’ (pp. 217) The first two paragraphs in ‘Vaccines against nicotine under evaluation in clinical trials’ (pp. 218) with the exception of the last sentence in the second paragraph ‘Cytos AG, Schlieren Switzerland’ (pp. 218) ‘Phase II study of vaccine NIB002’ (pp. 218) ‘Celtic pharma holdings LP’ (pp. 219) with the exception of the third-to-last and fourth-to-last sentences ‘Nabi Inc’ (pp. 220) with the exception of the last two sentences ‘Chilka Ltd and other competitors developing nicotine vaccines’ (pp. 220) ‘Further developments to expect’ (pp. 220)